AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of Switching From Intermittently Scanned to Real-time Continuous Glucose Monitoring on Diabetes Management in Adults With Type 2 Diabetes (Switch CGM T2D)

Recruitingn/aAges 18 Years - anyAllLMC Diabetes & Endocrinology Ltd.
💬

In plain words

What the trial is, and whether it could suit you

The goal of this prospective study is to evaluate diabetes outcomes and patient experience following a switch from second generation intermittently scanned continuous glucose monitor (isCGM) to real-time continuous glucose monitor (rtCGM) compared with participants with continued isCGM use among adults with insulin-treated type 2 diabetes (T2D) in a specialist endocrinology clinic setting in Canada. The study aims include: Primary outcome - Evaluate change in percent time in range (TIR) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with participants with continued second generation isCGM use. Secondary outcomes - Compare glycemic and metabolic outcomes (ie. additional CGM metrics, HbA1c, and weight), and outcomes related to diabetes management (ie. self-reported hypoglycemia and change in total daily dose \[TDD\] of insulin) at

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * 18 years or older * Clinical diagnosis of T2D ≥ one year * Using insulin for ≥ 6 months * Continued FreeStyle Libre® 2 isCGM device (isCGM cohort) as of the study start date * Would like to switch from a FreeStyle Libre® 2 isCGM device to a Dexcom® G7 rtCGM device (rtCGM switch cohort) as of the study start date * Baseline HbA1c ≥ 7.5% * Known rtCGM/isCGM start date (month and year) * Exclusive use of isCGM for ≥ 3 months * Data on LibreView platforms have percent sensor capture ≥ 70% for 14 days of available data up to 6 months prior to index date * ≥ 1 value for TIR (%) up to 6 months (± 6 weeks) prior to index date * ≥ 1 value for HbA1c (%) up to 6 months (± 6 weeks) prior to index date * Data consent Exclusion Criteria: * Have a prior history of rtCGM within 12 months of the index date * Recent or expectant change to antihyperglycemic medications or doses within 30 days of index date * Recent or expectant titration of insulin dose ≥ 20% within 30 days of index date * Are pregnant at the time of study enrollment or intending to become pregnant during the study * Used the isCGM or rtCGM for \< 3 months * Using continuous subcutaneous insulin infusion
💊

What it tests

  • real-time continuous glucose monitor
📍

Where

1 site
LMC Diabetes & Endocrinology Ltd.
Toronto, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy